Mazdutide Outperforms Semaglutide in Type 2 Diabetes and Obesity: Results from the Phase 3 DREAMS-3 Trial

Previously Published on hcplive.com — Innovent Biologics has announced impressive results from the DREAMS-3 phase 3 clinical trial, demonstrating the superiority of mazdutide—a dual GLP-1/glucagon (GCG) receptor agonist—over semaglutide in treating type 2 diabetes (T2D) and comorbid obesity. The trial confirmed that mazdutide achieved greater reductions in HbA1c and body weight, meeting its primary endpoint and reinforcing its potential as a next-generation metabolic therapy. Mazdutide outperforms Semaglutide in Type 2 Diabetes and Obesity.

The 32-Week Study

In this 32-week, randomized study involving 349 patients, participants received either mazdutide 6 mg or semaglutide 1 mg. Eligible participants were adults with T2D, a BMI ≥28 kg/m², and poorly controlled blood glucose despite lifestyle interventions, with or without stable metformin therapy. The study’s primary goal was the proportion achieving both HbA1c <7% and ≥10% weight loss from baseline, while secondary outcomes included greater weight reduction, fasting glucose, lipid profiles, and blood pressure changes.

Results

Results revealed that a significantly higher proportion of patients in the Mazdutide group achieved key composite outcomes compared to Semaglutide. The mean HbA1c reduction was –2.03% for mazdutide versus –1.84% for semaglutide, while average weight loss reached 10.29% and 6%, respectively (P < .05). Importantly, mazdutide maintained a favorable safety profile, consistent with earlier trials, with most adverse events limited to mild to moderate gastrointestinal symptoms.

Dr. Linong Ji of Peking University People’s Hospital emphasized mazdutide’s dual mechanism, noting its superior glucose-lowering and weight-loss effects and potential to deliver multiple metabolic benefits. Similarly, Lei Qian, Chief R&D Officer at Innovent, highlighted that DREAMS-3 further validates mazdutide as a promising therapy for broad cardiometabolic improvement.

Following its success in DREAMS-3, Innovent Biologics plans to expand mazdutide research into conditions such as metabolic dysfunction-associated steatohepatitis (MASH), heart failure with preserved ejection fraction (HFpEF), and obesity. As the world’s first approved GLP-1/GCG dual receptor agonist, mazdutide represents a significant advancement in the treatment of T2D and obesity, potentially setting a new benchmark in metabolic care.

Read the full article about how Mazdutide outperforms Semaglutide on hcplive.com